159 related articles for article (PubMed ID: 25632433)
1. Structural elucidation of potential impurities in Azilsartan bulk drug by HPLC.
Zhou W; Zhou Y; Sun L; Zou Q; Wei P; Ouyang P
J AOAC Int; 2014; 97(6):1552-62. PubMed ID: 25632433
[TBL] [Abstract][Full Text] [Related]
2. Quantification and structural elucidation of potential impurities in agomelatine active pharmaceutical ingredient.
Liu Y; Chen L; Ji Y
J Pharm Biomed Anal; 2013; 81-82():193-201. PubMed ID: 23666256
[TBL] [Abstract][Full Text] [Related]
3. A Rapid Novel HPLC Method for Estimation of Eight Related Compounds in Azilsartan Kamedoxomil and Identification of Degradation Compounds by Using LC-MS.
Sreenivasulu J; Venkata Ramana P; Sampath Kumar Reddy G; Nagaraju ChV; Thirumalai Rajan S; Eswaraiah S
J Chromatogr Sci; 2015 Oct; 53(9):1463-74. PubMed ID: 25925084
[TBL] [Abstract][Full Text] [Related]
4. Structural elucidation of the impurities in Enzalutamide bulk drug and the development, validation of corresponding HPLC method.
Ma X; Zhou W; Zou Q; Ouyang P
J Pharm Biomed Anal; 2016 Nov; 131():436-443. PubMed ID: 27664386
[TBL] [Abstract][Full Text] [Related]
5. Identification, characterization and HPLC quantification of process-related impurities in Trelagliptin succinate bulk drug: Six identified as new compounds.
Zhang H; Sun L; Zou L; Hui W; Liu L; Zou Q; Ouyang P
J Pharm Biomed Anal; 2016 Sep; 128():18-27. PubMed ID: 27209451
[TBL] [Abstract][Full Text] [Related]
6. Stability-indicating reversed-phase HPLC method development and characterization of impurities in vortioxetine utilizing LC-MS, IR and NMR.
Liu L; Cao N; Ma X; Xiong K; Sun L; Zou Q; Yao L
J Pharm Biomed Anal; 2016 Jan; 117():325-32. PubMed ID: 26412721
[TBL] [Abstract][Full Text] [Related]
7. Isolation, structure characterization and quantification of related impurities in asperosaponin VI.
Ji D; Liu YF; Wang QH; Zhang CF; Yang ZL
Chin J Nat Med; 2013 Jul; 11(4):419-26. PubMed ID: 23845554
[TBL] [Abstract][Full Text] [Related]
8. Stability Indicating RP-HPLC Method for Estimation of Potential Impurities in Ledipasvir and Characterization of a New Degradation Impurity.
Siva Kumar R; Sravan Kumar KV; Kondareddy L; Yogeshwara KR; Manish G; Jeenet J; Nitesh K
J Chromatogr Sci; 2018 May; 56(5):383-395. PubMed ID: 29474520
[TBL] [Abstract][Full Text] [Related]
9. Identification, Characterization and HPLC Quantification of Process-Related Impurities in Bepotastine Besilate Bulk Drug.
Zhang C; Han C; Sun L; Yu J; Zou Q
Drug Res (Stuttg); 2020 Jan; 70(1):12-22. PubMed ID: 31539916
[TBL] [Abstract][Full Text] [Related]
10. Isolation and characterization of process related impurities of olanzapine using HPLC and ESI-MS/MS.
Rao RN; Raju AN; Narsimha R; Babu GR
J Sep Sci; 2008 Jan; 31(1):107-18. PubMed ID: 18080239
[TBL] [Abstract][Full Text] [Related]
11. Characterization and quantitative determination of impurities in piperaquine phosphate by HPLC and LC/MS/MS.
Dongre VG; Karmuse PP; Ghugare PD; Gupta M; Nerurkar B; Shaha C; Kumar A
J Pharm Biomed Anal; 2007 Jan; 43(1):186-95. PubMed ID: 16916594
[TBL] [Abstract][Full Text] [Related]
12. A Stability Indicating Method Development and Validation for Separation of Process Related Impurities and Characterization of Unknown Impurities of Tyrosine Kinase Inhibitor Ibrutinib Using QbD Approach by RP-HPLC, NMR Spectroscopy and ESI-MS.
Gopireddy RR; Maruthapillai A; Mahapatra S
J Chromatogr Sci; 2021 Sep; 59(9):830-846. PubMed ID: 33420506
[TBL] [Abstract][Full Text] [Related]
13. A high pH based reversed-phase high performance liquid chromatographic method for the analysis of aminoglycoside plazomicin and its impurities.
Tan L; Wlasichuk KB; Schmidt DE; Campbell RL; Hirtzer P; Cheng L; Karr DE
J Pharm Biomed Anal; 2012 Jul; 66():75-84. PubMed ID: 22459505
[TBL] [Abstract][Full Text] [Related]
14. Isolation and characterization of degradation products of citalopram and process-related impurities using RP-HPLC.
Rao RN; Raju AN; Narsimha R
J Sep Sci; 2008 Jun; 31(10):1729-38. PubMed ID: 18481321
[TBL] [Abstract][Full Text] [Related]
15. Identification and Characterization of Asulam Impurities in Self Made Bulk Batch Synthesis and Quantification by RP-HPLC Method.
Mahaboob Basha D; Venkata Reddy G; Gopi Krishna Y; Kumara Swamy BE; Vijay R
J AOAC Int; 2018 Sep; 101(5):1448-1460. PubMed ID: 29673416
[TBL] [Abstract][Full Text] [Related]
16. Forced degradation, LC-UV, MS(n) and LC-MS-TOF studies on azilsartan: Identification of a known and three new degradation impurities.
Kaushik D; Kaur J; Paul Kaur V; Saini B; Bansal Y; Bansal G
J Pharm Biomed Anal; 2016 Feb; 120():202-11. PubMed ID: 26752083
[TBL] [Abstract][Full Text] [Related]
17. A Multi-Analyte LC-MS/MS Method for Determination and Quantification of Six Nitrosamine Impurities in Sartans like Azilsartan, Valsartan, Telmisartan, Olmesartan, Losartan and Irbesartan.
Gopireddy RR; Maruthapillai A; Mahapatra S
J Chromatogr Sci; 2024 Feb; 62(2):147-167. PubMed ID: 35830866
[TBL] [Abstract][Full Text] [Related]
18. Highly efficient, selective, sensitive and stability indicating RP-HPLC-UV method for the quantitative determination of potential impurities and characterization of four novel impurities in eslicarbazepine acetate active pharmaceutical ingredient by LC/ESI-IT/MS/MS.
Thomas S; Bharti A; Maddhesia PK; Shandilya S; Agarwal A; Dharamvir ; Biswas S; Bhansal V; Gupta AK; Tewari PK; Mathela CS
J Pharm Biomed Anal; 2012 Mar; 61():165-75. PubMed ID: 22178334
[TBL] [Abstract][Full Text] [Related]
19. HPLC analysis, semi-preparative HPLC preparation and identification of three impurities in salidroside bulk drug.
Peng Y; Luo J; Lu Q; Chen X; Xie Y; Chen L; Yang W; Du S
J Pharm Biomed Anal; 2009 Apr; 49(3):828-32. PubMed ID: 19167183
[TBL] [Abstract][Full Text] [Related]
20. Separation and estimation of process-related impurities of gefitinib by reverse-phase high-performance liquid chromatography.
Chandrashekara KA; Udupi A; Reddy CG
J Chromatogr Sci; 2014 Sep; 52(8):799-805. PubMed ID: 23897663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
